Login / Signup

First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial.

Christopher J FunesRyan A MaceErik A MacklinScott R PlotkinJustin T JordanChristopher J Funes
Published in: Journal of neuro-oncology (2019)
The d3RP-NF2 was well accepted, highly feasible, and resulted in sustained improvements in QoL in patients with NF2 who are deaf or have significant hearing loss.
Keyphrases
  • hearing loss
  • signaling pathway
  • lps induced
  • pi k akt
  • nuclear factor
  • oxidative stress
  • double blind
  • open label
  • placebo controlled
  • phase iii
  • inflammatory response
  • phase ii
  • randomized controlled trial